Asia branded business recovery uncertainty
Asia branded declined 9% YoY due to softer traction in certain markets; management expects recovery from Q4 but no specific timeline.
AJANTPHARM / Q3-FY26 / risks
Keep the risk register visible.
Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Competition in GLP-1 market in India
Analyst raised concern about aggressive competition in India for GLP-1; management acknowledged 15-20+ competitors expected.
Forex volatility impact on margins
Mark-to-market forex loss of INR 61 crore in 9M impacted EBITDA margin; management excluded it from guidance but risk remains.
Execution risk in new geographies and M&A
Management mentioned potential entry into Latin America and active M&A pipeline; execution and integration risks are high.